The pharmaceutical giant Zydus Cadila told that the US Food and Drug Administration known as USFDA have given approval to market Mesalamine Delayed-Release tablets USP in the USA market.
Once the Zydus Cadila shared the news, the Cadila share has encountered a wide jump in its share. The company share saw over 10% vertically increase.
Today morning around 10 AM the share goes up to the level of Rs. 534 which is about 10 % jump.
To file an abridged New Drug Application for a generic form of Lialda, Zydus Cadila was the first pharmaceutical company.
The company will be manufactured the drug at Moraiya plant located at Ahmedabad.
The company told in a press release that Lialda is used for the treatment of ulcerative colitis. Almost 700,000 lakh people get affected by this disease in the United States.